Fludarabine Phosphate Injection Section 19A Approval – Now Available from Pro Pharmaceuticals Group

Update – PBS listing effective 1 January

Fludarabine phosphate injection has now been formally listed on the Pharmaceutical Benefits Scheme (PBS) effective 1 January.

This PBS listing supports access to fludarabine for eligible patients, including use in appropriate hospital-managed and outpatient oncology settings.

PBS items: 15144C, 15145D

Further details are available on the PBS website:https://www.pbs.gov.au/medicine/item/15144C-15145D

Pro Pharmaceuticals Group continues to support supply of Fludarabine Phosphate Injection, USP (Areva, USA) in Australia under the TGA Section 19A pathway.

_________________________________________________________

Dear Healthcare Professional,

Pro Pharmaceuticals Group wishes to advise that the Australian registered product FLUDARABINE JUNO (fludarabine phosphate 50 mg powder for injection vial, AUST R: 147831) is currently in shortage, as listed on the TGA Medicines Shortage Database.

To ensure continuity of care, the TGA has granted approval under Section 19A of the Therapeutic Goods Act 1989 for supply of an alternative product:

Fludarabine Phosphate Injection, USP 50 mg/2 mL (25 mg/mL) Single-Dose Vial (Areva, USA)

This product is registered and marketed in the United States and is approved for import and supply in Australia until 31 August 2026, specifically for the treatment of B-cell chronic lymphocytic leukaemia.

Key Details

• Equivalent active ingredient and strength to the Australian product

• Ready-to-use sterile solution (no reconstitution required)

• Supplied as a single-dose vial

• Storage: Refrigerated at 2–8°C

• Labelled in English

We encourage hospital pharmacies and oncology units to circulate this information internally and contact us regarding supply.

📧 Orders & Enquiries: orders@propg.com.au📞 Phone: 1300 077 674🌐 Website: www.propg.com.au